Shots:
- F2G & Shionogi have reported the topline P-III (OASIS) trial data assessing olorofim (PO) vs AmBisome followed by SoC in 225 pts with invasive aspergillosis whose infection is either refractory to or unsuitable for azole therapy
- Trial met its 1EP of non-inferiority, with a rate of all-cause mortality of 23.8% vs 24.3% at Day 42, plus demonstrated favorable safety; data to be presented at a future conference & submitted to regulatory authorities in the US by F2G and in EU & Asia by Shionogi
- Olorofim (F901318) is an orotomide-class antifungal candidate with a novel mechanism of action, demonstrating activity against a broad range of Aspergillus species, incl. strains resistant to currently approved therapies
Ref: Globenewswire | Image: F2G and Shionogi | Press Release
Related News: Shionogi Secures US FDA Approval of Xocova for PEP COVID-19 Prevention
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
